-Vegetative symptoms (anorexia, weight loss, middle and late insomnia)
-Diurnal mood variation
-Psychomotor agitation or retardation
-Autonomous and pervasive symptoms
-Acute onset
-Family history of depression
-Dose of imipramine (or equivalent dose of another heterocyclic) above 125–150 mg/day
-Blood levels of desipramine (or imipramine and desipramine) above 200 ng/ml, and nortryptiline between 50 and 150 ng/ml
|
-Coexistence of other significant psychiatric disturbances (particularly with hysterical or externalizing features)
-Chronic symptoms
-Psychotic features
-Hypochondriacal concerns or predominant somatic features
-Previous drug trial failure(s)
-History of sensitivity to adverse reactions
|